Preventing perinatal HIV acquisition; current gaps and future perspectives.
Journal
Current opinion in HIV and AIDS
ISSN: 1746-6318
Titre abrégé: Curr Opin HIV AIDS
Pays: United States
ID NLM: 101264945
Informations de publication
Date de publication:
20 Aug 2024
20 Aug 2024
Historique:
medline:
28
8
2024
pubmed:
28
8
2024
entrez:
28
8
2024
Statut:
aheadofprint
Résumé
Although current treatment could eradicate vertical transmission, in 2022, 130 000 infants acquired HIV globally. HIV suppression with antiretroviral therapy (ART) transforms survival for people living with HIV (PLWH), and prevents transmission, including vertical. International guidelines recommend lifelong ART for PLWH, consequently perinatal HIV acquisition reflects implementation gaps in the HIV care cascade. We summarize these gaps, exploring potential novel approaches and therapeutic innovations towards eliminating vertical HIV transmission. Multifactorial challenges continue to underpin gaps in the HIV care cascade, including accessibility, availability and sustainability of HIV testing, prevention and treatment, alongside stigma, gender-based violence and poverty. Long-acting ART may be important in preventing perinatal HIV acquisition, with early data demonstrating tolerability and efficacy of injectable ART throughout pregnancy, both as HIV treatment and prevention. Carefully selected long-acting broadly neutralizing antibodies (bNAbs) matching circulating, exposing viral envelope sequences have demonstrated safety, clinical trials are ongoing to demonstrate efficacy. Emerging clinical studies should prioritize pregnant/lactating people and infants to ensure such therapies are well tolerated and efficacious. Alongside therapeutic innovation, programmatic strategies must address social and economic challenges, ensuring sustainable HIV treatment/prevention programmes and facilitating global elimination of blood-borne viruses.
Identifiants
pubmed: 39196368
doi: 10.1097/COH.0000000000000881
pii: 01222929-990000000-00110
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
Copyright © 2024 The Author(s). Published by Wolters Kluwer Health, Inc.
Références
Waters L, People First Charter. People First Charter 2023. Available at: https://peoplefirstcharter.org/. [Accessed 1 July 2024]
The Lancet HIV Putting people first in communication about HIV. Lancet HIV 2023; 10:e623.
Bamford A, Foster C, Lyall H. Infant feeding: emerging concepts to prevent HIV transmission. Curr Opin Infect Dis 2024; 37:8–16.
The Working Group on Mother-To-Child Transmission of HIV Rates of mother-to-child transmission of HIV-1 in Africa, America, and Europe: results from 13 perinatal studies. J Acquir Immune Defic Syndr Hum Retrovirol 1995; 8:506–510.
Humphrey JH, Marinda E, Mutasa K, et al. ZVITAMBO study group Mother to child transmission of HIV among Zimbabwean women who seroconverted postnatally: prospective cohort study. BMJ 2010; 341:c6580.
Morrison CS, Demers K, Kwok C, et al. Plasma and cervical viral loads among Ugandan and Zimbabwean women during acute and early HIV-1 infection. AIDS 2010; 24:573–582.
Joint United Nations Programme on HIV/AIDS (UNAIDS). The path that ends AIDS: UNAIDS Global AIDS Update 2023. Geneva, Switzerland 2023.
World Health Organization. Triple elimination of mother-to-child transmission of HIV, hepatitis B and syphilis in Asia and the Pacific baseline report 2018. Manila, Philippines: World Health Organization Regional Office for the Western Pacific, Licence: CC BY-NC-SA 3.0 IGO; 2018.
NHS England. National Health Service Infectious Diseases in Pregnancy Screening Programme. Integrated Screening Outcomes Surveillance Service (ISOSS) annual report 2022. Updated June 2023. In: Service ISOS, editor. 2022.
The Joint United Nations Programme on HIV/AIDS (UNAIDS) UN. UNAIDS data 2023. 2023.
World Health Organization. Global HIV Programme. In: The WHO Department of Global HIV HaSTIP, editor. 2024.
The Joint United Nations Programme on HIV/AIDS (UNAIDS). Global AIDS Strategy 2021–2026. End inequalities. End AIDS. Geneva, Switzerland: UNAIDS; 2021.
Unified Budget RaAFU, The Joint United Nations Programme on HIV/AIDS (UNAIDS). Paediatric AIDS, vertical transmission. In: Unified Budget RaAFU, UNAIDS, editor. Geneva, Switzerland, 2024.
The Global Alliance. The Global Alliance to End AIDS in Children by 2030. Geneva, Switzerland, 2024.
The Joint United Nations Programme on HIV/AIDS (UNAIDS). Result area 3: paediatric AIDS, vertical transmission. In: UNAIDS, editor. Geneva, Switzerland, 2023.
The Joint United Nations Programme on HIV/AIDS (UNAIDS). Fact sheet - latest global and regional statistics on the status of the AIDS epidemic. In: UNAIDS, editor. Geneva, Switzerland, 2023.
Nielsen-Saines K, Watts DH, Veloso VG, et al. NICHD HPTN 040/PACTG 1043 Protocol Team Three postpartum antiretroviral regimens to prevent intrapartum HIV infection. N Engl J Med 2012; 366:2368–2379.
Aebi-Popp K, Kahlert CR, Crisinel PA, et al. Swiss Mother and Child HIV Cohort Study (SHCS) Transfer of antiretroviral drugs into breastmilk: a prospective study from the Swiss Mother and Child HIV Cohort Study. J Antimicrob Chemother 2022; 77:3436–3442.
Matthews LT, Jaggernath M, Kriel Y, et al. Oral PrEP uptake, adherence, and persistence during periconception periods among women in South Africa: an intervention study. AIDS 2024.
Kintu K, Malaba TR, Nakibuka J, et al. DolPHIN-2 Study Group Dolutegravir versus efavirenz in women starting HIV therapy in late pregnancy (DolPHIN-2): an open-label, randomised controlled trial. Lancet HIV 2020; 7:e332–e339.
Townsend CL, Byrne L, Cortina-Borja M, et al. Earlier initiation of ART and further decline in mother-to-child HIV transmission rates. AIDS 2014; 28:1049–1057.
World Health Organization. Policy Brief: WHO recommendation: Elective C-section should not be routinely recommended to women living with HIV. 2018.
Fotso JC, Cleland JG, Kouo Ngamby M, et al. Pregnancy risks and contraceptive use among postpartum mothers in Cameroon: implications for improving the coverage of postpartum family planning services. Reprod Health 2023; 20:2.
World Health Organization. Consolidated guidelines on HIV prevention, testing, treatment, service delivery and monitoring: recommendations for a public health approach In: Global HIV HaSPH, Guidelines Review Committee, editor. Geneva, Switzerland, 2021.
The Antiretroviral Pregnancy Registry. 2023 Available at: www.apregistry.com. [Accessed 24 July 2024].
Bukkems VE, Necsoi C, Hidalgo Tenorio C, et al. Tenofovir alafenamide plasma concentrations are reduced in pregnant women living with human immunodeficiency virus (HIV): data from the PANNA Network. Clin Infect Dis 2022; 75:623–629.
Mesfin YM, Kibret KT, Taye A. Is protease inhibitors based antiretroviral therapy during pregnancy associated with an increased risk of preterm birth? Systematic review and a meta-analysis. Reprod Health 2016; 13:30.
Chi BH, Kacanek D, Brown E, et al. Maternal and Pregnancy Outcomes in Women Initiating and Declining PrEP in Pregnancy: IMPAACT 2009. In: Conference on Retroviruses and Opportunistic Infections (CROI) 2024; Denver, Colorado, 2024.
Fairlie L, Lavies D, Kalk E, et al. Safety surveillance for PrEP in pregnant and breastfeeding women. Front Reprod Health 2023; 5:1221101.
World Health Organization. Policy Brief: Consolidated guidelines on HIV testing services for a changing epidemic. 2019.
de Beer S, Kalk E, Kroon M, et al. A longitudinal analysis of the completeness of maternal HIV testing, including repeat testing in Cape Town, South Africa. J Int AIDS Soc 2020; 23:e25441.
Okusanya B, Kimaru LJ, Mantina N, et al. Interventions to increase early infant diagnosis of HIV infection: a systematic review and meta-analysis. PLoS One 2022; 17:e0258863.
British HIV Association (BHIVA). British HIV Association guidelines for the management of HIV in pregnancy and postpartum 2018 (2020 third interim update). 2020.
Tang Y, Woodward BO, Pastor L, et al. Endogenous retroviral envelope syncytin induces HIV-1 spreading and establishes HIV reservoirs in placenta. Cell Rep 2020; 30:4528.e4–4539.e4.
Amin O, Powers J, Bricker KM, Chahroudi A. Understanding viral and immune interplay during vertical transmission of HIV: implications for cure. Front Immunol 2021; 12:757400.
De Andreis C, Simoni G, Rossella F, et al. HIV-1 proviral DNA polymerase chain reaction detection in chorionic villi after exclusion of maternal contamination by variable number of tandem repeats analysis. Aids 1996; 10:711–715.
John GC, Nduati RW, Mbori-Ngacha DA, et al. Correlates of mother-to-child human immunodeficiency virus type 1 (HIV-1) transmission: association with maternal plasma HIV-1 RNA load, genital HIV-1 DNA shedding, and breast infections. J Infect Dis 2001; 183:206–212.
Prendergast AJ, Goga AE, Waitt C, et al. Transmission of CMV, HTLV-1, and HIV through breastmilk. Lancet Child Adolesc Health 2019; 3:264–273.
Ndirangu J, Viljoen J, Bland RM, et al. Cell-free (RNA) and cell-associated (DNA) HIV-1 and postnatal transmission through breastfeeding. PLoS One 2012; 7:e51493.
Bunders MJ, van der Loos CM, Klarenbeek PL, et al. Memory CD4(+)CCR5(+) T cells are abundantly present in the gut of newborn infants to facilitate mother-to-child transmission of HIV-1. Blood 2012; 120:4383–4390.
Mattila PS, Nykänen A, Eloranta M, Tarkkanen J. Adenoids provide a microenvironment for the generation of CD4+, CD45RO+, L-selectin–, CXCR4+, CCR5+ T lymphocytes, a lymphocyte phenotype found in the middle ear effusion. International Immunology 2000; 12:1235–1243.
Myburgh D, Rabie H, Slogrove AL, et al. Horizontal HIV transmission to children of HIV-uninfected mothers: a case series and review of the global literature. Int J Infect Dis 2020; 98:315–320.
Ivy W 3rd, Dominguez KL, Rakhmanina NY, et al. Premastication as a route of pediatric HIV transmission: case-control and cross-sectional investigations. J Acquir Immune Defic Syndr 2012; 59:207–212.
Johnson LF, Stinson K, Newell ML, et al. The contribution of maternal HIV seroconversion during late pregnancy and breastfeeding to mother-to-child transmission of HIV. J Acquir Immune Defic Syndr 2012; 59:417–425.
Sibiude J, Le Chenadec J, Mandelbrot L, et al. Update of perinatal human immunodeficiency virus type 1 transmission in France: zero transmission for 5482 mothers on continuous antiretroviral therapy from conception and with undetectable viral load at delivery. Clin Infect Dis 2023; 76:e590–e598.
Benali G, Ramdin T, Ballot D. An audit of mother to child HIV transmission rates and neonatal outcomes at a tertiary hospital in South Africa. BMC Res Notes 2019; 12:586.
Johnson EL, Boggavarapu S, Johnson ES, et al. Human cytomegalovirus enhances placental susceptibility and replication of human immunodeficiency virus type 1 (HIV-1), which may facilitate in utero HIV-1 transmission. J Infect Dis 2018; 218:1464–1473.
Mbachu II, Ejikunle SD, Anolue F, et al. Relationship between placenta malaria and mother to child transmission of HIV infection in pregnant women in South East Nigeria. Malar J 2020; 19:97.
Duarte G. What is the influence of preeclampsia on vertical transmission of HIV? BJOG 2017; 124:928.
Maswime S, Pule C, Mtshali Z, et al. HIV, placental lesions, and adverse perinatal outcomes. J Infect Dis 2021; 224: (12 Suppl 2): S691–S693.
Reynolds LP, Caton JS, Redmer DA, et al. Evidence for altered placental blood flow and vascularity in compromised pregnancies. J Physiol 2006; 572 (Pt 1):51–58.
Rouzioux C, Costagliola D, Burgard M, et al. Timing of mother-to-child HIV-1 transmission depends on maternal status. The HIV Infection in Newborns French Collaborative Study Group. AIDS 1993; 7: (Suppl 2): S49–S52.
Chen KT, Segú M, Lumey LH, et al. New York City Perinatal AIDS Collaborative Transmission Study (PACTS) Group Genital herpes simplex virus infection and perinatal transmission of human immunodeficiency virus. Obstet Gynecol 2005; 106:1341–1348.
Johnson LF, Lewis DA. The effect of genital tract infections on HIV-1 shedding in the genital tract: a systematic review and meta-analysis. Sex Transm Dis 2008; 35:946–959.
International Perinatal HIV Group Duration of ruptured membranes and vertical transmission of HIV-1: a meta-analysis from 15 prospective cohort studies. AIDS 2001; 15:357–368.
Garcia-Tejedor A, Perales A, Maiques V. Duration of ruptured membranes and extended labor are risk factors for HIV transmission. Int J Gynaecol Obstet 2003; 82:17–23.
Andiman W, Bryson Y, et al. International Perinatal HIV Group The mode of delivery and the risk of vertical transmission of human immunodeficiency virus type 1--a meta-analysis of 15 prospective cohort studies. N Engl J Med 1999; 340:977–987.
Owor M, DeMarrais P, Baltrusaitis K, et al. 1077BF: breast milk reservoir, tenofovir levels, and HIV transmission among breastfeeding mothers. In: Conference on Retroviruses and Opportunistic Infections (CROI) 2024; 3–6 March 2024; Denver, Colorado, USA, 2024.
Rutagwera DG, Molès JP, Kankasa C, et al. Recurrent severe subclinical mastitis and the risk of HIV transmission through breastfeeding. Front Immunol 2022; 13:822076.
Embree JE, Njenga S, Datta P, et al. Risk factors for postnatal mother-child transmission of HIV-1. AIDS 2000; 14:2535–2541.
Van de Perre P, Simonon A, Hitimana DG, et al. Infective and antiinfective properties of breastmilk from HIV-1-infected women. Lancet 1993; 341:914–918.
Ruff AJ, Coberly J, Halsey NA, et al. Prevalence of HIV-1 DNA and p24 antigen in breast milk and correlation with maternal factors. J Acquir Immune Defic Syndr (1988) 1994; 7:68–73.
Mangé A, Tuaillon E, Viljoen J, et al. Elevated concentrations of milk (2-microglobulin are associated with increased risk of breastfeeding transmission of HIV-1 (Vertical Transmission Study). J Proteome Res 2013; 12:5616–5625.
Bengu N, Cromhout GZ, Adland E, et al. Sex-Specific Innate Immune Selection in Vertical HIV Transmission and cART-Free Aviraemia in Males. In Conference on Retroviruses and Opportunistic Infections (CROI) 2024; 3–6 March 2024; Denver, Colorado, USA; 2024.
Adland E, Millar J, Bengu N, et al. Sex-specific innate immune selection of HIV-1 in utero is associated with increased female susceptibility to infection. Nat Commun 2020; 11:1767.
Shalekoff S, Da Costa Dias B, Loubser S, et al. Higher CCR5 density on CD4 + T cells in mothers and infants is associated with increased risk of in-utero HIV-1 transmission. AIDS 2024.
Maiques V, García-Tejedor A, Perales A, Navarro C. Intrapartum fetal invasive procedures and perinatal transmission of HIV. Eur J Obstet Gynecol Reprod Biol 1999; 87:63–67.
Charurat M, Datong P, Matawal B, et al. Timing and determinants of mother-to-child transmission of HIV in Nigeria. Int J Gynaecol Obstet 2009; 106:8–13.
Raru TB, Merga BT, Deressa A, et al. Coverage and determinants of HIV testing and counseling services among mothers attending antenatal care in sub-Saharan African countries: a multilevel analysis. BMC Public Health 2024; 24:910.
Phelanyane FM, Heekes A, Smith M, et al. Prevention of vertical transmission of HIV in Khayelitsha, South Africa: a contemporary review of services after 20 years. S Afr Med J 2023; 113:14–19.
Mboya E, Mizinduko M, Balandya B, et al. HIV burden and the global fast-track targets progress among pregnant women in Tanzania calls for intensified case finding: analysis of 2020 antenatal clinics HIV sentinel site surveillance. PLoS One 2023; 18:e0285962.
Abadan SS, Hawryluk L, Montandon M, et al. Preexposure prophylaxis among pregnant and lactating people in 18 PEPFAR-supported countries: a review of HIV strategies and guidelines. Glob Health Sci Pract 2022; 10:e2200129.
Mvududu R, Bheemraj K, Nelson A, et al. PrEP discontinuation and high HIV incidence in South African pregnant and postpartum women. In: Conference on Retroviruses and Opportunistic Infections (CROI) 2024; Denver, Colorado, 2024.
Atukunda EC, Owembabazi M, Pratt MC, et al. A qualitative exploration to understand barriers and facilitators to daily oral PrEP uptake and sustained adherence among HIV-negative women planning for or with pregnancy in rural Southwestern Uganda. J Int AIDS Soc 2022; 25:e25894.
Khadka N, Gorbach PM, Nyemba DC, et al. Evaluating the use of oral preexposure prophylaxis among pregnant and postpartum adolescent girls and young women in Cape Town, South Africa. Front Reprod Health 2023; 5:1224474.
Beesham I, Dovel K, Mashele N, et al. Barriers to oral HIV preexposure prophylaxis (PrEP) adherence among pregnant and postpartum women from Cape Town, South Africa. AIDS Behav 2022; 26:3079–3087.
Matthews LT, Atukunda EC, Owembabazi M, et al. High PrEP uptake and objective longitudinal adherence among HIV-exposed women with personal or partner plans for pregnancy in rural Uganda: a cohort study. PLoS Med 2023; 20:e1004088.
Ramraj T, Abdelatif N, Chirinda W, et al. A risk measurement tool for targeted HIV prevention measures amongst young pregnant and lactating women in South Africa. BMC Public Health 2022; 22:1277.
Mutale W, Freeborn K, Graybill LA, et al. Addition of HIV self-test kits to partner notification services to increase HIV testing of male partners of pregnant women in Zambia: two parallel randomised trials. Lancet Glob Health 2021; 9:e1719–e1729.
(USAID) USAfID. Advancing Gender Equality and Preventing & Responding to Gender-Based Violence to Achieve Sustained HIV Epidemic Control. In: HIV/AIDS Oo, editor. Washington DC, USA: United States Agency for International Development; 2024.
Boyce CL, Sils T, Ko D, et al. Maternal human immunodeficiency virus (HIV) drug resistance is associated with vertical transmission and is prevalent in infected infants. Clin Infect Dis 2022; 74:2001–2009.
Momplaisir F, Hussein M, Kacanek D, et al. Perinatal depressive symptoms, human immunodeficiency virus (HIV) suppression, and the underlying role of antiretroviral therapy adherence: a longitudinal mediation analysis in the IMPAACT P1025 Cohort. Clin Infect Dis 2021; 73:1379–1387.
Alhassan Y, Twimukye A, Malaba T, et al. ’I fear my partner will abandon me’: the intersection of late initiation of antenatal care in pregnancy and poor ART adherence among women living with HIV in South Africa and Uganda. BMC Pregnancy Childbirth 2022; 22:566.
The Republic of Uganda Ministry of Health. Consolidated guidelines for the prevention and treatment of HIV and AIDS in Uganda. In: Health Mo, editor. Uganda, 2022.
Gupta R, Kemp S, Kamelian K, et al. HIV transmission dynamics and population-wide drug resistance in rural South Africa. Res Sq 2023.
Tadesse BT, Tsai O, Chala A, et al. Prevalence and correlates of pre-treatment hiv drug resistance among HIV-infected children in Ethiopia. Viruses 2019; 11.:E877.
Jacobs TG, Schouwenburg S, Penazzato M, et al. Penta Clinical Pharmacology Working Group, PADO-HIV 5 participants What babies need: accelerating access to current and novel antiretroviral drugs in neonates through pharmacokinetic studies. Lancet HIV 2022; 9:e649–e657.
Bekker A, Salvadori N, Rabie H, et al. Single-dose PK/safety of DTG-dispersible tablets in neonates supports multi-dosing: Petite-DTG Study. In: Conference on Retroviruses and Opportunistic Infections (CROI) 2024; Denver, Colorado, 2024.
The UN Refugee Agency (USA for UNHCR). Refugee Statistics 2023. In: The United Nations High Commissioner for Refugees (UNHCR), editor. Washington DC, United States of America, 2023.
Biraro S, Farley SM, Musinguzi J, et al. Prevalence of HIV and viral load suppression among refugees in Uganda, October to December 2021. In: Conference on Retroviruses and Opportunistic Infections (CROI) 2024; Denver, Colorado, USA, 2024.
Moyo E, Moyo P, Murewanhema G, et al. Key populations and sub-Saharan Africa's HIV response. Front Public Health 2023; 11:1079990.
Phillips TK, Teasdale CA, Geller A, et al. Approaches to transitioning women into and out of prevention of mother-to-child transmission of HIV services for continued ART: a systematic review. J Int AIDS Soc 2021; 24:e25633.
Lyatuu GW, Naburi H, Mwashemele S, et al. Effect of peer-mother interactive programme on prevention of mother-to-child HIV transmission outcomes among pregnant women on antiretroviral treatment in routine healthcare in Dar es Salaam, Tanzania. PLoS Glob Public Health 2022; 2:e0000256.
Stangl AL, Sebany M, Kapungu C, et al. Is HIV index testing and partner notification safe for adolescent girls and young women in low- and middle-income countries? J Int AIDS Soc 2020; 23: (Suppl 5): e25562.
Gleeson HS, Oliveras Rodriguez CA, Hatane L, Hart D. Ending AIDS by 2030: the importance of an interlinked approach and meaningful youth leadership. J Int AIDS Soc 2018; 21: (Suppl 1):
Ruel T, Penazzato M, Zech JM, et al. Novel approaches to postnatal prophylaxis to eliminate vertical transmission of HIV. Glob Health Sci Pract 2023; 11:e2200401.
McFarland EJ, Cunningham CK, Muresan P, et al. International Maternal Pediatric Adolescent AIDS Clinical Trials Network (IMPAACT) P1112 Team Safety, tolerability, and pharmacokinetics of a long-acting broadly neutralizing human immunodeficiency virus type 1 (HIV-1) monoclonal antibody VRC01LS in HIV-1-exposed newborn infants. J Infect Dis 2021; 224:1916–1924.
Joseph Davey DL, Pintye J, Baeten JM, et al. Emerging evidence from a systematic review of safety of preexposure prophylaxis for pregnant and postpartum women: where are we now and where are we heading? J Int AIDS Soc 2020; 23:e25426.
Delany-Moretlwe S, Hughes JP, Bock P, et al. HPTN 084 study group Cabotegravir for the prevention of HIV-1 in women: results from HPTN 084, a phase 3, randomised clinical trial. Lancet 2022; 399:1779–1789.
Nair G, Celum C, Szydlo D, et al. Adherence, safety, and choice of the monthly dapivirine vaginal ring or oral emtricitabine plus tenofovir disoproxil fumarate for HIV preexposure prophylaxis among African adolescent girls and young women: a randomised, open-label, crossover trial. Lancet HIV 2023; 10:e779–e789.
Bunge K, Balkus JE, Fairlie L, et al. DELIVER: a safety study of a dapivirine vaginal ring and oral PrEP for the prevention of HIV during pregnancy. J Acquir Immune Defic Syndr 2024; 95:65–73.
Owor M, Noguchi L, Horne E, et al. Dapivirine ring safety and drug detection in breastfeeding mother-infant pairs. In: Conference on Retroviruses and Opportunistic Infections (CROI) 2023; 19–22 February 2023; Seattle, Washington, USA, 2023.
Erlwanger A, Rocroi I, Kirtley S, Hemelaar J. Perinatal outcomes associated with preexposure prophylaxis for HIV prevention during pregnancy: a systematic review and meta-analysis. EClinicalMedicine 2024; 70:102532.
Joseph Davey DL, Bekker LG, Bukusi EA, et al. Where are the pregnant and breastfeeding women in new preexposure prophylaxis trials? The imperative to overcome the evidence gap. Lancet HIV 2022; 9:e214–e222.
Cresswell FV, Lamorde M. Implementation of long-acting antiretroviral therapy in low-income and middle-income countries. Curr Opin HIV AIDS 2022; 17:127–134.
Kityo CM, Mambule IK, Sokhela S, et al. Randomized trial of cabotegravir and rilpivirine long-acting in Africa (CARES): week 48 results. In: Conference on Retroviruses and Opportunistic Infections (CROI) 2024; Denver, Colorado, USA, 2024/
Patel P, Ford SL, Baker M, et al. Pregnancy outcomes and pharmacokinetics in pregnant women living with HIV exposed to long-acting cabotegravir and rilpivirine in clinical trials. HIV Med 2023; 24:568–579.
Derbalah A, Karpick HC, Maize H, et al. Role of islatravir in HIV treatment and prevention: an update. Curr Opin HIV AIDS 2022; 17:240–246.
Markowitz M, Gettie A, St Bernard L, et al. Once-weekly oral dosing of MK-8591 protects male rhesus macaques from intrarectal challenge with SHIV109CP3. J Infect Dis 2020; 221:1398–1406.
ClinicalTrials.gov. Oral ISL QM as PrEP in cisgender women at high risk for HIV-1 infection (MK-8591-022) (Impower-022), Merck Sharp & Dohme LLC, 2023 [updated 17 October 2023]. Clinical trials ID number NCT04644029]. Available at: https://clinicaltrials.gov/study/NCT04644029?cond=HIV%20Infection&term=islatravir&rank=10. [Accessed 1 July 2024].
Segal-Maurer S, DeJesus E, Stellbrink HJ, et al. CAPELLA Study Investigators Capsid inhibition with lenacapavir in multidrug-resistant HIV-1 infection. N Engl J Med 2022; 386:1793–1803.
Bekerman E, Yant SR, VanderVeen L, et al. Long-acting lenacapavir acts as an effective preexposure prophylaxis in a rectal SHIV challenge macaque model. J Clin Invest 2023; 133:e167818.
Vidal SJ, Bekerman E, Hansen D, et al. Long-acting capsid inhibitor protects macaques from repeat SHIV challenges. Nature 2022; 601:612–616.
ClinicalTrials.gov, Gilead Sciences. Study of Lenacapavir and Emtricitabine/Tenofovir Disoproxil Fumarate (F/TDF) in Prevention of HIV in Cisgender Women in the United States (HPTN 102) (PURPOSE 3). In: Medicine NLo, editor. Bethesda, Maryland, USA, 2024.
ClinicalTrials.gov, Gilead Sciences. Pre-Exposure Prophylaxis Study of Lenacapavir and Emtricitabine/Tenofovir Alafenamide in Adolescent Girls and Young Women at Risk of HIV Infection (PURPOSE 1). Bethesda, Maryland, USA: National Library of Medicine; 2024.
Abrams EJ, Capparelli E, Ruel T, Mirochnick M. Potential of long-acting products to transform the treatment and prevention of human immunodeficiency virus (HIV) in infants, children, and adolescents. Clin Infect Dis 2022; 75: (Suppl 4): S562–S570.
Hessell AJ, Jaworski JP, Epson E, et al. Early short-term treatment with neutralizing human monoclonal antibodies halts SHIV infection in infant macaques. Nat Med 2016; 22:362–368.
Corey L, Gilbert PB, Juraska M, et al. HVTN 704/HPTN 085 and HVTN 703/HPTN 081 Study Teams Two randomized trials of neutralizing antibodies to prevent HIV-1 acquisition. N Engl J Med 2021; 384:1003–1014.
Meijers M, Vanshylla K, Gruell H, et al. Predicting in vivo escape dynamics of HIV-1 from a broadly neutralizing antibody. Proc Natl Acad Sci U S A 2021; 118:e2104651118.
Alba C, Malhotra S, Horsfall S, et al. Cost-effectiveness of broadly neutralizing antibodies for infant HIV prophylaxis in settings with high HIV burdens: a simulation modeling study. medRxiv 2023.
Cunningham CK, McFarland EJ, Morrison RL, et al. Safety, tolerability, and pharmacokinetics of the broadly neutralizing human immunodeficiency virus (HIV)-1 monoclonal antibody VRC01 in HIV-exposed newborn infants. J Infect Dis 2020; 222:628–636.
Ajibola G, Masheto G, Shapiro R. Antibody interventions in HIV: broadly neutralizing mAbs in children. Curr Opin HIV AIDS 2023; 18:217–224.
ClinicalTrials.gov. Evaluating the Safety and Antiviral Activity of Monoclonal Antibody VRC01 in Infants With HIV Receiving Combination Antiretroviral Therapy. Bethesda, Maryland, USA: National Library of Medicine, ClinicalTrials.gov; 2023.
ClinicalTrials.gov. Very Early Intensive Treatment of HIV-Infected Infants to Achieve HIV Remission. Bethesda, Maryland, USA: National Library of Medicine, ClinicalTrials.gov, 2023.
ClinicalTrials.gov. Evaluating the Safety and Pharmacokinetics of VRC01, VRC01LS, and VRC07-523LS, Potent Anti-HIV Neutralizing Monoclonal Antibodies, in HIV-1-Exposed Infants. Bethesda, Maryland, USA: National Library of Medicine, ClinicalTrials.gov, 2023.
IMPAACT Network. IMPAACT 2037. Open-Label, Phase I study of the safety and pharmacokinetics of PGT121.414.LS alone and in combination with VRC07-523LS in infants exposed to HIV-1 2020. Available at: https://www.impaactnetwork.org/studies/impaact2037. [Accessed 1 July 2024].
PedMAb consortium. PedMAb - seeking innovative ways to protect children from getting HIV from their mothers 2023. Available at: https://pedmab.w.uib.no/. [Accessed 1 July 2024].
Thomas AS, Moreau Y, Jiang W, et al. Preexisting infant antibody-dependent cellular cytotoxicity associates with reduced HIV-1 acquisition and lower morbidity. Cell Rep Med 2021; 2:100412.
Meyer-Rath G, Jamieson L, Pillay Y. What will it take for an injectable ARV to change the face of the HIV epidemic in high-prevalence countries? Considerations regarding drug costs and operations. J Int AIDS Soc 2023; 26: (Suppl 2): e26106.
World Health Organization. Fact Sheet: HIV drug resistance Geneva, Switzerland, 2024.
Hitchcock AM, Kufel WD, Dwyer KAM, Sidman EF. Lenacapavir: A novel injectable HIV-1 capsid inhibitor. Int J Antimicrob Agents 2024; 63:107009.
Markowitz M, Grobler JA. Islatravir for the treatment and prevention of infection with the human immunodeficiency virus type 1. Curr Opin HIV AIDS 2020; 15:27–32.
Frattari GS, Caskey M, Søgaard OS. Broadly neutralizing antibodies for HIV treatment and cure approaches. Curr Opin HIV AIDS 2023; 18:157–163.
Juraska M, Bai H, deCamp AC, et al. Prevention efficacy of the broadly neutralizing antibody VRC01 depends on HIV-1 envelope sequence features. Proc Natl Acad Sci U S A 2024; 121:e2308942121.
Moldt B, Parvangada A, Martin R, et al. Evaluation of broadly neutralizing antibody sensitivity by genotyping and phenotyping for qualifying participants to HIV clinical trials. J Acquir Immune Defic Syndr 2021; 88:61–69.
Tipoe T, Fidler S, Frater J. An exploration of how broadly neutralizing antibodies might induce HIV remission: the ‘vaccinal’ effect. Curr Opin HIV AIDS 2022; 17:162–170.
Dugdale CM, Ufio O, Alba C, et al. Cost-effectiveness of broadly neutralizing antibody prophylaxis for HIV-exposed infants in sub-Saharan African settings. J Int AIDS Soc 2023; 26:e26052.
Gaebler C, Caskey M. Broadly neutralizing antihuman immunodeficiency virus antibodies in infants: promising new tools for prevention of mother-to-child transmission? J Infect Dis 2020; 222:525–527.
World Health Organization Triple elimination initiative: validation of elimination of mother-to-child transmission of HIV, syphilis and hepatitis B. Geneva, Switzerland:World Health Organization; 2024.
Lampe MA, Nesheim SR, Oladapo KL, et al. Achieving elimination of perinatal HIV in the United States. Pediatrics 2023; 151:e2022059604.
World Health Organization Global HIV, Hepatitis and STIs Programmes. Geneva, Switzerland:World Health Organization; 2024.